U.S. markets close in 3 hours 45 minutes
  • S&P 500

    4,238.06
    -9.38 (-0.22%)
     
  • Dow 30

    34,253.24
    -226.36 (-0.66%)
     
  • Nasdaq

    14,131.15
    +61.73 (+0.44%)
     
  • Russell 2000

    2,331.05
    -4.75 (-0.20%)
     
  • Crude Oil

    71.43
    +0.52 (+0.73%)
     
  • Gold

    1,866.00
    -13.60 (-0.72%)
     
  • Silver

    28.08
    -0.06 (-0.22%)
     
  • EUR/USD

    1.2129
    +0.0022 (+0.18%)
     
  • 10-Yr Bond

    1.4920
    +0.0300 (+2.05%)
     
  • GBP/USD

    1.4118
    +0.0001 (+0.01%)
     
  • USD/JPY

    109.9950
    +0.3600 (+0.33%)
     
  • BTC-USD

    40,341.26
    +3,956.82 (+10.88%)
     
  • CMC Crypto 200

    1,010.42
    +41.57 (+4.29%)
     
  • FTSE 100

    7,146.68
    +12.62 (+0.18%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments

·5 min read
Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

When the Food and Drug Administration (FDA) approved Biogen's (NASDAQ: BIIB) aducanumab -- now marketed as Aduhelm -- for treating Alzheimer's Disease, it marked the end of a long drought. No matter how that turns out, the low bar for approval set by the FDA is likely to open the floodgates for Alzheimer's treatments. It has investors in Cassava Sciences (NASDAQ: SAVA) and Annovis Bio (NYSEMKT: ANVS) excited about their candidates, which are currently in clinical trials.